Immune to Cancer: The CRI Blog
-
2022 International Cancer Immunotherapy Conference Highlights from Day 3
The third day of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22) focused on two relatively new… -
2022 International Cancer Immunotherapy Conference Highlights from Day 2
The second day of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22) started off by delving deeper… -
2022 International Cancer Immunotherapy Conference Highlights from Day 1
Back for the first time since the COVID-19 pandemic began, the sixth annual CRI-ENCI-AACR International Cancer Immunotherapy… -
From Autoimmunity to Cancer Cures: How Diabetes May Hold the Key to Improving Immunotherapy, with Dr. Andrea Schietinger
Biologically, cancer and autoimmunity don’t seem to have much in common. In fact, they appear to be… -
Immunotherapy for Rare Cancers: New Horizons and New Hope
Rare cancers are more common than many realize. Collectively, they account for nearly one in four cases… -
Understanding and Overcoming Disparities in Cancer Treatment and Care
Cancer not only affects each person differently, but it can also affect different communities overall in different… -
ASCO 2022 Recap: Cancer Immunotherapy Updates
Since the first FDA approval in 2011 to treat cancer patients with checkpoint immunotherapy, doctors have sought… -
ASCO 2022 Preview: The Latest Insights from the Front Lines of Cancer Immunotherapy
CRI’s PRINCE Trial featured at ASCO22, along with sessions that highlight the latest clinical advances in checkpoint…
-
Beyond the Prognosis and Treatment: Cancer Survivorship
Cancer survivors have a diverse range of experiences with their diagnoses, treatment, and life after cancer.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.